{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:01:11Z","timestamp":1766088071053,"version":"3.41.2"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Even 3\u00a0years into the COVID-19 pandemic, questions remain about how to safely and effectively vaccinate vulnerable populations. A systematic analysis of the safety and efficacy of the COVID-19 vaccine in at-risk groups has not been conducted to date.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This study involved a comprehensive search of PubMed, EMBASE, and Cochrane Central Controlled Trial Registry data through 12 July 2022. Post-vaccination outcomes included the number of humoral and cellular immune responders in vulnerable and healthy populations, antibody levels in humoral immune responders, and adverse events.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 23 articles assessing 32 studies, were included. The levels of IgG (SMD = \u22121.82, 95% CI [\u22122.28, \u22121.35]), IgA (SMD = \u22120.37, 95% CI [\u22120.70, \u22120.03]), IgM (SMD = \u22120.94, 95% CI [\u22121.38, \u22120.51]), neutralizing antibodies (SMD = \u22121.37, 95% CI [\u22122.62, \u22120.11]), and T cells (SMD = \u22121.98, 95% CI [\u22123.44, \u22120.53]) were significantly lower in vulnerable than in healthy populations. The positive detection rates of IgG (OR = 0.05, 95% CI [0.02, 0.14]) and IgA (OR = 0.03, 95% CI [0.01, 0.11]) antibodies and the cellular immune response rates (OR = 0.20, 95% CI [0.09, 0.45]) were also lower in the vulnerable populations. There were no statistically significant differences in fever (OR = 2.53, 95% CI [0.11, 60.86]), chills (OR = 2.03, 95% CI [0.08, 53.85]), myalgia (OR = 10.31, 95% CI [0.56, 191.08]), local pain at the injection site (OR = 17.83, 95% CI [0.32, 989.06]), headache (OR = 53.57, 95% CI [3.21, 892.79]), tenderness (OR = 2.68, 95% CI [0.49, 14.73]), and fatigue (OR = 22.89, 95% CI [0.45, 1164.22]) between the vulnerable and healthy populations.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Seroconversion rates after COVID-19 vaccination were generally worse in the vulnerable than healthy populations, but there was no difference in adverse events. Patients with hematological cancers had the lowest IgG antibody levels of all the vulnerable populations, so closer attention to these patients is recommended. Subjects who received the combined vaccine had higher antibody levels than those who received the single vaccine.<\/jats:p>","DOI":"10.3389\/fphar.2023.1144824","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T17:57:23Z","timestamp":1687629443000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["COVID-19 vaccination effectiveness and safety in vulnerable populations: a meta-analysis of 33 observational studies"],"prefix":"10.3389","volume":"14","author":[{"given":"Hui-Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Yang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Qiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Yang","family":"Xian-Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"704110","DOI":"10.3389\/fimmu.2021.704110","article-title":"COVID-19 vaccination in fragile patients: Current evidence and an harmonized transdisease trial","volume":"12","author":"Agrati","year":"2021","journal-title":"Front. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet (London, Engl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijid.2021.01.016","article-title":"Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review","volume":"104","author":"Chen","year":"2021","journal-title":"Int. J. Infect. Dis. IJID"},{"key":"B4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/ajt.16775","article-title":"Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients","volume":"22","author":"Del Bello","year":"2022","journal-title":"Am. J. Transplant."},{"key":"B5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.kint.2021.10.040","article-title":"A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis","volume":"101","author":"Espi","year":"2022","journal-title":"Kidney Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann. rheumatic Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jtho.2021.10.015","article-title":"Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: A prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses","volume":"17","author":"Gounant","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"E793","DOI":"10.1503\/cmaj.210673","article-title":"Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis","volume":"193","author":"Goupil","year":"2021","journal-title":"CMAJ Can. Med. Assoc. J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"20140138","DOI":"10.1098\/rstb.2014.0138","article-title":"Biological challenges to effective vaccines in the developing world","volume":"370","author":"Grassly","year":"2015","journal-title":"Philosophical Trans. R. Soc. Lond. Ser. B, Biol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1111\/ajt.16615","article-title":"Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus","volume":"21","author":"Grupper","year":"","journal-title":"Am. J. Transplant."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2215\/CJN.03500321","article-title":"Humoral response to the pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis","volume":"16","author":"Grupper","year":"","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am. J. Hematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet (London, Engl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"eabd1525","DOI":"10.1126\/scitranslmed.abd1525","article-title":"Development and deployment of COVID-19 vaccines for those most vulnerable","volume":"13","author":"Koff","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMp2006761","article-title":"Covid-19 and immunity in aging populations - a new research agenda","volume":"383","author":"Koff","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/v13050756","article-title":"Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech)","volume":"13","author":"Korth","year":"2021","journal-title":"Viruses"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.jinf.2020.04.019","article-title":"Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients","volume":"81","author":"Lee","year":"2020","journal-title":"J. Infect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.cmi.2021.07.031","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1","volume":"27","author":"Levy","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"B19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/jnci\/djab174","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients","volume":"114","author":"Ligumsky","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"B20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1126\/science.abe5938","article-title":"Understanding COVID-19 vaccine efficacy","volume":"370","author":"Lipsitch","year":"2020","journal-title":"Sci. (New York, NY)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"m2516","DOI":"10.1136\/bmj.m2516","article-title":"Diagnostic accuracy of serological tests for Covid-19: Systematic review and meta-analysis","volume":"370","author":"Lisboa Bastos","year":"2020","journal-title":"BMJ Clin. Res. ed)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s40588-021-00157-9","article-title":"COVID-19: Diagnostics, therapeutic advances, and vaccine development","volume":"8","author":"Majid","year":"2021","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","article-title":"Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer","volume":"7","author":"Massarweh","year":"2021","journal-title":"JAMA Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): An investigator-initiated, single-centre, open-label study","volume":"3","author":"Moor","year":"2021","journal-title":"Lancet Rheumatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.3390\/jcm11092565","article-title":"Serological response to three, four and five doses of SARS-CoV-2 vaccine in kidney transplant recipients","volume":"11","author":"Osmanodja","year":"2022","journal-title":"J. Clin. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.annonc.2021.04.020","article-title":"Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients","volume":"32","author":"Palich","year":"","journal-title":"Ann. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.annonc.2021.06.018","article-title":"High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers","volume":"32","author":"Palich","year":"","journal-title":"Ann. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41408-022-00684-8","article-title":"Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: A systematic review","volume":"12","author":"Piechotta","year":"2022","journal-title":"Blood cancer J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: Preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jhep.2021.04.020","article-title":"Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients","volume":"75","author":"Rabinowich","year":"2021","journal-title":"J. hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.32394\/pe.75.01","article-title":"The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19","volume":"75","author":"Rastawicki","year":"2021","journal-title":"Przeglad Epidemiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e150175","DOI":"10.1172\/JCI150175","article-title":"Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients","volume":"131","author":"Sattler","year":"2021","journal-title":"J. Clin. investigation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/bjh.17918","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients","volume":"196","author":"Shem-Tov","year":"2022","journal-title":"Br. J. Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jrsm.1429","article-title":"Optimally estimating the sample standard deviation from the five-number summary","volume":"11","author":"Shi","year":"2020","journal-title":"Res. synthesis methods"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2215\/CJN.03700321","article-title":"Early humoral responses of hemodialysis patients after COVID-19 vaccination with BNT162b2","volume":"16","author":"Speer","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"B38","doi-asserted-by":"publisher","first-page":"100178","DOI":"10.1016\/j.lanepe.2021.100178","article-title":"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine","volume":"9","author":"Stumpf","year":"2021","journal-title":"Lancet regional health Eur."},{"key":"B39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/nep.13974","article-title":"Humoral and cellular immune response to severe acute respiratory syndrome coronavirus-2 vaccination in haemodialysis and kidney transplant patients","volume":"27","author":"Swai","year":"2022","journal-title":"Nephrol. Carlt. Vic."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jhep.2021.08.008","article-title":"Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases","volume":"75","author":"Thuluvath","year":"2021","journal-title":"J. hepatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"102743","DOI":"10.1016\/j.jaut.2021.102743","article-title":"A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases","volume":"125","author":"Tzioufas","year":"2021","journal-title":"J. Autoimmun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"101455","DOI":"10.1016\/j.arr.2021.101455","article-title":"Underrepresentation of older adults in clinical trials on COVID-19 vaccines: A systematic review","volume":"71","author":"Veronese","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","article-title":"Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors","volume":"22","author":"Waissengrin","year":"2021","journal-title":"Lancet Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1158\/2159-8290.CD-21-1072","article-title":"Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors","volume":"11","author":"Waldhorn","year":"2021","journal-title":"Cancer Discov."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.kint.2021.04.006","article-title":"Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients","volume":"99","author":"Yanay","year":"2021","journal-title":"Kidney Int."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2001526","DOI":"10.1183\/13993003.01526-2020","article-title":"Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients","volume":"56","author":"Yu","year":"2020","journal-title":"Eur. Respir. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1144824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T17:57:26Z","timestamp":1687629446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1144824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":46,"alternative-id":["10.3389\/fphar.2023.1144824"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1144824","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"article-number":"1144824"}}